In brief
Australian and international researchers project that global cervical cancer incidence will climb 20.2 % and deaths will surge 39.3 % by 2050, despite the disease being largely preventable. The sharpest gains are expected in sub‑Saharan Africa, where cases could rise 88.7 % and deaths 95.4 %. The study calls for expanded HPV vaccination, screening and treatment to meet WHO elimination targets.
Australian researchers and collaborators have modelled that global cervical cancer cases and deaths will rise by 20.2 % and 39.3 % respectively by 2050, even as the disease remains largely preventable, according to a study published in Nature Medicine.
The research pulled incidence, mortality and health‑loss data from 204 worldwide jurisdictions dated from 1990 through 2023, and used statistical algorithms to project future trends. In 2023 an estimated 887,000 new cases and 369,000 deaths were recorded; by 2050 those figures are forecast to climb to 1.08 million cases and 522,000 deaths.
Methodological Framework
The modelling approach combined historical surveillance data with demographic projections to estimate year‑by‑year changes. Researchers adjusted for disparities in reporting quality across countries and applied age‑standardization to allow comparisons between low‑income and high‑income settings.
Age‑standardized incidence rates in 2023 were more than four times higher in low‑income than in high‑income countries, while mortality rates were over seven times higher, the study reports.
Sub‑Saharan Africa Faces the Largest Surge
Sub‑Saharan Africa is projected to experience the most dramatic increases: cases could climb 88.7 % and deaths 95.4 % by 2050, bringing the number of deaths to an estimated 206,000. This region’s projected burden will almost double its current death toll.
Across the seven global regions examined, none is on track to meet the World Health Organization’s cervical‑cancer elimination threshold of fewer than four cases per 100,000 women by 2050 if current trends persist.
"The findings underscore the need for broader access to HPV vaccination, screening and treatment," the authors say, noting that worldwide distribution of those interventions remains uneven.
In 2023, reliance on HPV vaccination and screening varied widely, with many low‑income countries reporting limited availability. The study stresses that without expanded preventive measures and effective outreach, the projected upward trajectory may continue.
Healthcare policymakers, especially in high‑burden regions, should prioritize scaling up vaccination programs and establishing affordable screening pathways to curtail the projected increase in cervical cancer incidence and mortality.
